PORR AG Selects @GlobalTrade™ for Digitization of Bank Guarantees & Surety Bonds
14.5.2020 18:24:00 EEST | Business Wire | Press release
GlobalTrade Corporation (GTC) has announced today that PORR AG (PORR), one of the largest construction companies in Austria, has selected its @GlobalTrade™ Multi-bank Trade Finance Platform for managing its bank guarantees and surety bonds. PORR employees will use the Platform to access transactions on-line from any place in the world and electronically connect PORR Treasury with its financial institutions.
PORR will manage outgoing transactions with @GlobalTrade™ Guarantee Issuance System http://www.globaltradecorp.com/solutions/standby-lc-guarantee-issuance/ and incoming transactions with @GlobalTrade™ Guarantee Receipt System http://www.globaltradecorp.com/solutions/standby-lc-guarantee-receipt/.
‘The decision to adopt an electronic platform for the management of guarantees has been made before the Covid-19 pandemic,’ said Alfred Gabler, Head of Group Treasury PORR AG. ‘With the new reality and the need to access real time information from outside the office as well as to digitize as many financial processes as possible, those platforms have become a must have for every company,’ added Gabler.
‘With the need to work from home, our clients have told us how much they appreciate the ability to access their trade finance transactions remotely. Being able to create, approve and send new transactions to their financial institutions electronically is a great advantage’, said Stephen Andersen, GTC’s Vice President Professional Services & Client Support. ‘We are honored that PORR has trusted GTC to start the project under the Covid-19 restrictions. GTC has been implementing projects remotely for many years, which allows us to serve our clients efficiently even during these challenging times,’ added Andersen.
About PORR
Driving innovation for excellence – that’s what PORR stands for since already over 150 years. With around 20,000 employees and a production output of around EUR 5.6 billion (as at 31.12.2019), it is one of the largest construction companies in Austria and among Europe’s leading providers in the sector. As a full-service provider, PORR offers every service in building construction, civil engineering and infrastructure construction, covering the entire value chain. PORR focuses on its home markets Austria, Germany, Switzerland, Poland, Czech Republic, Slovakia and Romania. On selected international project markets such as in Norway, the UAE and Qatar, PORR focuses on export products in tunnel construction, railway construction and civil engineering. The PORR share is listed in the prime market of Vienna Stock Exchange. Find more information at porr-group.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005634/en/
Contact information
GlobalTrade Corporation
Mitesh Patel
Tel: +1 416 661 8520
E-mail: info@globaltradecorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom